Original Research3 December 2013
    Author, Article, and Disclosure Information

    Abstract

    Background:

    Introduction of a universal varicella vaccine program for U.S. children in 1996 sparked concern that less-frequent exposure to varicella would decrease external boosting of immunity to varicella zoster virus and thereby increase incidence of herpes zoster (HZ).

    Objective:

    To determine whether the varicella vaccination program has influenced trends in HZ incidence in the U.S. population older than 65 years.

    Design:

    Retrospective study of Medicare claims.

    Setting:

    Medicare, 1992 through 2010.

    Participants:

    2 848 765 beneficiaries older than 65 years.

    Measurements:

    Annual HZ incidence from 1992 through 2010; rate ratios (RRs) for HZ incidence by age, sex, and race or ethnicity; and state-level varicella vaccination coverage.

    Results:

    281 317 incident cases of HZ occurred. Age- and sex-standardized HZ incidence increased 39% from 10.0 per 1000 person-years in 1992 to 13.9 per 1000 person-years in 2010 with no evidence of a statistically significant change in the rate of increase after introduction of the varicella vaccination program. Before introduction of this program, HZ incidence was higher in women (RR, 1.21 [95% CI, 1.19 to 1.24]) than men and was lower in black persons (RR, 0.51 [CI, 0.48 to 0.53]) and Hispanic persons (RR, 0.76 [CI, 0.72 to 0.81]) than white persons. In a model adjusted for sex, age, and calendar year from 1997 to 2010, HZ incidence did not vary by state varicella vaccination coverage (RR, 0.9998 [CI, 0.9993 to 1.0003]).

    Limitation:

    Uncertain level and consistency of health-seeking behavior and access and uncertain accuracy of disease coding.

    Conclusion:

    Age-specific HZ incidence increased in the U.S. population older than 65 years even before implementation of the childhood varicella vaccination program. Introduction and widespread use of the vaccine did not seem to affect this increase. This information is reassuring for countries considering universal varicella vaccination.

    Primary Funding Source:

    None.

    References

    • 1. Atkinson WWolfe S, and Hamborsky JEpidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed. Washington, DC Public Health Foundation 2012. Google Scholar
    • 2. Kilgore PEKruszon-Moran DSeward JFJumaan AVan Loon FPForghani Bet alVaricella in Americans from NHANES III: implications for control through routine immunization. J Med Virol2003;70: S111-8. [PMID: 12627498] CrossrefMedlineGoogle Scholar
    • 3. Yawn BPSaddier PWollan PCSt Sauver JLKurland MJ, and Sy LSA population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc2007;82:1341-9. [PMID: 17976353] CrossrefMedlineGoogle Scholar
    • 4. Gilden DHKleinschmidt-DeMasters BKLaGuardia JJMahalingam R, and Cohrs RJNeurologic complications of the reactivation of varicella-zoster virus. N Engl J Med2000;342:635-45. [PMID: 10699164] CrossrefMedlineGoogle Scholar
    • 5. Drolet MBrisson MSchmader KELevin MJJohnson ROxman MNet alThe impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ2010;182:1731-6. [PMID: 20921251] CrossrefMedlineGoogle Scholar
    • 6. Marin MGüris DChaves SSSchmid S, and Seward JFAdvisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC)Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2007;56:RR-4 1-40. [PMID: 17585291] MedlineGoogle Scholar
    • 7. Sadzot-Delvaux CRentier BWutzler PAsano YSuga SYoshikawa Tet alVaricella vaccination in Japan, South Korea, and Europe. J Infect Dis2008;197: S185-90. [PMID: 18419395] CrossrefMedlineGoogle Scholar
    • 8. Hope-Simpson REThe nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med1965;58:9-20. [PMID: 14267505] CrossrefMedlineGoogle Scholar
    • 9. Brisson MGay NJEdmunds WJ, and Andrews NJExposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine2002;20:2500-7. [PMID: 12057605] CrossrefMedlineGoogle Scholar
    • 10. Gershon AALaRussa PSteinberg SMervish NLo SH, and Meier PThe protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis1996;173:450-3. [PMID: 8568309] CrossrefMedlineGoogle Scholar
    • 11. Thomas SLWheeler JG, and Hall AJContacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet2002;360:678-82. [PMID: 12241874] CrossrefMedlineGoogle Scholar
    • 12. Donahue JGKieke BAGargiullo PMJumaan AOBerger NRMcCauley JSet alHerpes zoster and exposure to the varicella zoster virus in an era of varicella vaccination. Am J Public Health2010;100:1116-22. [PMID: 20075320] CrossrefMedlineGoogle Scholar
    • 13. Chaves SSSantibanez TAGargiullo P, and Guris DChickenpox exposure and herpes zoster disease incidence in older adults in the U.S. Public Health Rep2007;122:155-9. [PMID: 17357357] CrossrefMedlineGoogle Scholar
    • 14. Garnett GP and Grenfell BTThe epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiol Infect1992;108:513-28. [PMID: 1318219] CrossrefMedlineGoogle Scholar
    • 15. U.K. Health Protection Agency. Latest HPA modelling reveals chickenpox vaccination would lead to more shingles among elderly despite introduction of shingles vaccination [press release]. 17 September 2008. Accessed at www.hpa.org.uk/NewsCentre/NationalPressReleases/2008PressReleases/080917chickenpox/ on 1 July 2013. Google Scholar
    • 16. Ragozzino MWMelton LJKurland LTChu CP, and Perry HOPopulation-based study of herpes zoster and its sequelae. Medicine (Baltimore)1982;61:310-6. [PMID: 6981045] CrossrefMedlineGoogle Scholar
    • 17. Jumaan AO, Seward JF, Wooten K, Singelton J. Varicella and herpes zoster surveillance in the US, 1970–1994 [Abstract]. In: Programs and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America, San Diego, California, 9–12 October 2003. Alexandria, VA: Infectious Diseases Soc America; 2003: 899. Abstract 899. Google Scholar
    • 18. Mullooly JPRiedlinger KChun CWeinmann S, and Houston HIncidence of herpes zoster, 1997–2002. Epidemiol Infect2005;133:245-53. [PMID: 15816149] CrossrefMedlineGoogle Scholar
    • 19. Leung JHarpaz RMolinari NAJumaan A, and Zhou FHerpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin Infect Dis2011;52:332-40. [PMID: 21217180] CrossrefMedlineGoogle Scholar
    • 20. Russell MLSchopflocher DPSvenson L, and Virani SNSecular trends in the epidemiology of shingles in Alberta. Epidemiol Infect2007;135:908-13. [PMID: 17291380] CrossrefMedlineGoogle Scholar
    • 21. Harpaz ROrtega-Sanchez IR, and Seward JFAdvisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC)Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2008;57:RR-5 1-30. [PMID: 18528318] MedlineGoogle Scholar
    • 22. Centers for Disease Control and Prevention (CDC)Adult vaccination coverage—United States, 2010. MMWR Morb Mortal Wkly Rep2012;61:66-72. [PMID: 22298302] MedlineGoogle Scholar
    • 23. ResDac. Accessed at www.resdac.org on 1 July 2013. Google Scholar
    • 24. Agency for Healthcare Research and Quality. Creation of New Race-Ethnicity Codes and Socioeconomic Status (SES) Indicators for Medicare Beneficiaries. 2008. Accessed at www.ahrq.gov/qual/medicareindicators/medicareindicators2.htm on 24 January 2012. Google Scholar
    • 25. Day JCPopulation projections of the United States by age, sex, race, and Hispanic origin: 1995 to 2050. Washington, DC Government Printing Office 1996. Google Scholar
    • 26. Klein RJ and Schoenborn CAAge adjustment using the 2000 projected U.S. population. Healthy People 2010 Stat Notes2001;:1-10. [PMID: 11676466] MedlineGoogle Scholar
    • 27. Gnann JW and Whitley RJClinical practice. Herpes zoster. N Engl J Med2002;347:340-6. [PMID: 12151472] CrossrefMedlineGoogle Scholar
    • 28. Kleinbaum DKupper LMuller K, and Nizam AApplied Regression Analysis and Multivariable Methods. Washington, DC Duxbury Pr 1998. Google Scholar
    • 29. Centers for Disease Control and Prevention. U.S. Vaccination Coverage Reported via National Immunization Survey. 2013. Accessed at www.cdc.gov/vaccines/stats-surv/nis/ on 1 July 2013. Google Scholar
    • 30. Guris DJumaan AOMascola LWatson BMZhang JXChaves SSet alChanging varicella epidemiology in active surveillance sites—United States, 1995–2005. J Infect Dis2008;197: S71-5. [PMID: 18419413] CrossrefMedlineGoogle Scholar
    • 31. Adams DAGallagher KMJajosky RAKriseman JSharp PAnderson WJet alDivision of Notifiable Diseases and Healthcare Information, Office of Surveillance, Epidemiology, and Laboratory Services, CDCSummary of notifiable diseases—United States, 2011. MMWR Morb Mortal Wkly Rep2013;60:1-117. [PMID: 23820934] MedlineGoogle Scholar
    • 32. Tanuseputro PZagorski BChan KJ, and Kwong JCPopulation-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine2011;29:8580-4. [PMID: 21939721] CrossrefMedlineGoogle Scholar
    • 33. Jumaan AOYu OJackson LABohlke KGalil K, and Seward JFIncidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. J Infect Dis2005;191:2002-7. [PMID: 15897984] CrossrefMedlineGoogle Scholar
    • 34. Chao DYChien YZYeh YPHsu PS, and Lian IBThe incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000–2008. Epidemiol Infect2012;140:1131-40. [PMID: 21906410] CrossrefMedlineGoogle Scholar
    • 35. Mehta SKCohrs RJForghani BZerbe GGilden DH, and Pierson DLStress-induced subclinical reactivation of varicella zoster virus in astronauts. J Med Virol2004;72:174-9. [PMID: 14635028] CrossrefMedlineGoogle Scholar
    • 36. Ljungman PLönnqvist BGahrton GRingdén OSundqvist VA, and Wahren BClinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis1986;153:840-7. [PMID: 3009635] CrossrefMedlineGoogle Scholar
    • 37. Luby JPRamirez-Ronda CRinner SHull A, and Vergne-Marini PA longitudinal study of varicella-zoster virus infections in renal transplant recipients. J Infect Dis1977;135:659-63. [PMID: 192807] CrossrefMedlineGoogle Scholar
    • 38. Mossong JHens NJit MBeutels PAuranen KMikolajczyk Ret alSocial contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med2008;5:74. [PMID: 18366252] CrossrefMedlineGoogle Scholar
    • 39. Beiser AD'Agostino RBSeshadri SSullivan LM, and Wolf PAComputing estimates of incidence, including lifetime risk: Alzheimer's disease in the Framingham Study. The Practical Incidence Estimators (PIE) macro. Stat Med2000;19:1495-522. [PMID: 10844714] CrossrefMedlineGoogle Scholar
    • 40. Fleming DMBartelds AChapman RS, and Cross KWThe consistency of shingles and its significance for health monitoring. Eur J Epidemiol2004;19:1113-8. [PMID: 15678791] CrossrefMedlineGoogle Scholar
    • 41. Pérez-Farinós NOrdobás MGarcía-Fernández CGarcía-Comas LCañellas SRodero Iet alVaricella and herpes zoster in Madrid, based on the Sentinel General Practitioner Network: 1997–2004. BMC Infect Dis2007;7:59. [PMID: 17570859] CrossrefMedlineGoogle Scholar
    • 42. Joesoef RMHarpaz RLeung J, and Bialek SRChronic medical conditions as risk factors for herpes zoster. Mayo Clin Proc2012;87:961-7. [PMID: 23036671] CrossrefMedlineGoogle Scholar
    • 43. Thomas SL and Hall AJWhat does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis2004;4:26-33. [PMID: 14720565] CrossrefMedlineGoogle Scholar
    • 44. Opstelten WVan Essen GASchellevis FVerheij TJ, and Moons KGGender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol2006;16:692-5. [PMID: 16516488] CrossrefMedlineGoogle Scholar
    • 45. Tseng HFSmith NHarpaz RBialek SRSy LS, and Jacobsen SJHerpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA2011;305:160-6. [PMID: 21224457] CrossrefMedlineGoogle Scholar
    • 46. Insinga RPItzler RFPellissier JMSaddier P, and Nikas AAThe incidence of herpes zoster in a United States administrative database. J Gen Intern Med2005;20:748-53. [PMID: 16050886] CrossrefMedlineGoogle Scholar
    • 47. Fleming DMCross KWCobb WA, and Chapman RSGender difference in the incidence of shingles. Epidemiol Infect2004;132:1-5. [PMID: 14979582] CrossrefMedlineGoogle Scholar
    • 48. Schmader KGeorge LKBurchett BM, and Pieper CFRacial and psychosocial risk factors for herpes zoster in the elderly. J Infect Dis1998;178: S67-70. [PMID: 9852978] CrossrefMedlineGoogle Scholar
    • 49. Centers for Medicare & Medicaid Services (CMS), HHSMedicare program; revisions to payment policies and five-year review of and adjustments to the relative value units under the physician fee schedule for calendar year 2002. Final rule with comment period. Fed Regist2001;66:55245-503. [PMID: 11760761] MedlineGoogle Scholar
    • 50. Lu PJEuler GLJumaan AO, and Harpaz RHerpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine2009;27:882-7. [PMID: 19071175] CrossrefMedlineGoogle Scholar
    • 51. Yawn BPWollan P, and St Sauver JComparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? Am J Epidemiol2011;174:1054-61. [PMID: 21920944] CrossrefMedlineGoogle Scholar